Get started
Author

Lise Nouveau

Observed names: L. Nouveau, Nouveau, Lise, Nouveau, Lise Gilberte Francine
ORCID: 0009-0006-6719-3152
Observed ORCID: 0009-0006-6719-3152
OpenAlex ID: A5014093121
Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies
2021 · Lise Nouveau, Vanessa Buatois, et al. · European Journal of Immunology · 26
PDF
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
2023 · Anja Seckinger, Sara Majocchi, et al. · Journal of Hematology & Oncology · 24
PDF
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12
PDF
Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies
2025 · Gaëlle H. Martin, Siham Hedir, et al. · Frontiers in Immunology · 3
PDF
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies
2025 · Julien Montorfani, Eric Hatterer, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 4139: Functional human myeloid cells in BRGSF-HIS humanized mice enables myeloid-directed therapy assessment
2023 · Florence Renart-Depontieu, Gaëlle Martin, et al. · Cancer Research · 2
752P Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer
2022 · A. Seckinger, S. Majocchi, et al. · Annals of Oncology · 2
PDF
853 Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer
2022 · Anja Seckinger, Vanessa Buatois, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Combination of bispecific antibodies enable targeted TNFRSF agonism and effective antitumor activity
2026 · Lucie Diby, Pauline Malinge, et al. · Molecular Therapy
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S14 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S17 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S12 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S16 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S10 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Works count: 67
Citation count: 73
H-index: 3
I10-index: 3
Year
Topic
Type